RxDoctor Payments Data

Gerald Sullivan, MD

Family Medicine · Putnam, CTNPI 1154396927

Payments from drug & device makers

$2,382in general payments, 2019–2025

Across 158 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$669
  • AstraZeneca$325
  • Pfizer$279
  • Novo Nordisk$169
  • Astellas Pharma US Inc$142
  • GSK$134
  • plus $664 from 14 others

What the payments were for

  • Food & beverage$2,26095%
  • Education$1225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,382 in reported general payments places this provider in the 80th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$2,914
Medicare patients
23
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$60,242
JardianceEmpagliflozin23$39,356
Bydureon BciseExenatide Microspheres13$27,048
JanuviaSitagliptin Phosphate16$25,137
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,016
MyrbetriqMirabegron38$16,502
XareltoRivaroxaban13$11,493
MovantikNaloxegol Oxalate14$5,267
SymbicortBudesonide/Formoterol Fumarate11$4,962
Gabapentin96$2,964
Wixela InhubFluticasone Propion/Salmeterol19$2,224
Famotidine86$1,855
Metoprolol Succinate111$1,668
Esomeprazole Magnesium18$1,424
Albuterol Sulfate HfaAlbuterol Sulfate40$1,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$279$60,24254 claims
Boehringer IngelheimJardiance$669$39,35623 claims
MerckJanuvia$76$25,13716 claims
GSKTrelegy Ellipta$134$19,01625 claims
Astellas Pharma US IncMyrbetriq$142$16,50238 claims
Johnson & JohnsonXarelto$96$11,49313 claims
AstraZenecaSymbicort$325$4,96211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Putnam

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →